icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018
Back grey_arrow_rt.gif
 
 
 
A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Na´ve, HCV GT1b-Infected Patients, with non-severe fibrosis : STREAGER
 
 
  Reported by Jules Levin
EASL 2018 April 11-15 Paris France
 
A. Abergel1, C. Hezode2, T. Asselah3, D. Larrey4, J. Gournay5, V. Loustaud-Ratti6, V. Di Martino7, I. Fouchard-Hubert8, D. Samuel9, B. Chanteranne1, M. Dodel1, F. Faure1, B. Pereira1, G. Lamblin1, C. Campos1, L. Muti1, M. Reymond1, C. Teilhet1
1Centre Hospitalier Universitaire de Clermont-Ferrand, 2Centre Hospitalier Universitaire Henri Mondor (AP-HP), 3Centre Hospitalier Universitaire Beaujon (AP-HP), 4Centre Hospitalier Universitaire de Montpellier, 5Centre Hospitalier Universitaire de Nantes, 6Centre Hospitalier Universitaire de Limoges, 7Centre Hospitalier Universitaire de Besanšon, 8Centre Hospitalier Universitaire de Angers, 9Centre Hospitalier Universitaire Paul Brousse (AP-HP)

0416181

0416182